Balance Sheet Components

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Prepaid and Other Current Assets

Prepaid and other current assets consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Prepaid research and development contract services	$	1,331	$	1,206
Advanced professional fees	297		243
Prepaid insurance	157		347
Other prepaid expenses and other current assets	116		101
Total prepaid and other current assets	$	1,901	$	1,897

Property and Equipment, Net

Property and equipment, net was comprised of the following (in thousands):


	March 31, 2025		December 31, 2024
Equipment	$	1,661	$	1,661
Furniture and fixtures	242		242
Leasehold improvements	132		132

Total property and equipment	2,035		2,035
Less: accumulated depreciation	(1,605)		(1,552)
Property and equipment, net	$	430	$	483

Depreciation expense for each of the three months ended March 31, 2025 and 2024 was $0.1 million.

Other long-term prepaid assets

Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $0.6 million for both March 31, 2025 and December 31, 2024.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Accrued professional fees	$	740	$	1,167
Accrued compensation and benefits	698		2,312
Accrued research and development	4,302		4,910

Other accrued expenses	30		26
Total accrued expenses	$	5,770	$	8,415

Elicio Therapeutics, Inc. 10-Q